PlaqueTec develops intracoronary liquid biopsy technology and operates BioCarta, a high-resolution cardiovascular data lake that captures proteomic biomarkers directly at sites of plaque formation. Its BIOPATTERN trial generates the platform’s proteomic and clinical data by sampling coronary concentration gradients to identify inflammation-related biomarkers and disease drivers. The company has leveraged its dataset to identify several potential therapeutic targets in subgroups of coronary artery disease patients. PlaqueTec is engaging with pharmaceutical and biotech partners interested in using its data for drug development and patient stratification. The recent $5 million financing will fund continued data collection, platform development, and partnership efforts to establish BioCarta as a foundational asset in cardiovascular research and precision medicine.

Total raised

$13M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2026